AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q1 FY26 results · Apr–Jun 2025
AstraZeneca Pharma India reported revenue from operations of ₹526.31 crore (up 35.8% from Q1 FY25) and net profit of ₹55.83 crore for Q1 FY26 (Apr–Jun 2025), on a standalone basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 526.31 | 387.52 | +35.8% | 480.48 | +9.5% |
| Other income | 11.24 | 8.35 | +34.7% | 16.15 | −30.4% |
| Total income | 537.55 | 395.87 | +35.8% | 496.63 | +8.2% |
| Profit before tax | 74.70 | (15.16) | Turned profit | 78.47 | −4.8% |
| Net profit for the period | 55.83 | (11.79) | Turned profit | 58.25 | −4.2% |
| EPS, basic (₹) | 22.33 | (4.72) | Turned profit | 23.30 | −4.2% |
| Net margin (%) | 10.6 | -3.0 | 12.1 |
Standalone
- Filed with BSE
- 14 Aug 2025, 17:25 IST
- Board meeting
- 14 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE